Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Niger to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs is driven by several factors, including customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Customers in Niger prefer bronchodilator drugs that are affordable and effective. They also prefer drugs that are easy to use and have minimal side effects. As a result, generic bronchodilator drugs are popular in the market, as they are cheaper than branded drugs and are considered to be equally effective.
Trends in the market: The market for bronchodilator drugs in Niger is growing steadily, driven by the increasing prevalence of respiratory diseases in the country. The demand for these drugs is also increasing due to the growing awareness about the importance of early diagnosis and treatment of respiratory diseases. Additionally, the government of Niger has taken several initiatives to improve the healthcare infrastructure in the country, which has led to an increase in the availability of these drugs.
Local special circumstances: Niger is a landlocked country in West Africa with a high prevalence of respiratory diseases. The country has a hot and dry climate, which can exacerbate respiratory symptoms. Additionally, air pollution is a major problem in urban areas, which can also contribute to the development of respiratory diseases. These local special circumstances have led to an increased demand for bronchodilator drugs in the country.
Underlying macroeconomic factors: The economy of Niger is largely dependent on agriculture, which accounts for over 40% of the country's GDP. The country is also heavily reliant on foreign aid and has a low level of industrialization. These factors have led to a relatively low level of healthcare spending in the country, which can limit the availability of bronchodilator drugs. However, the government of Niger has taken steps to improve the healthcare system in the country, which has led to an increase in the availability of these drugs. Additionally, the country is experiencing steady economic growth, which is expected to drive further growth in the bronchodilator drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
